Myeloproliferative neoplasms

por Kiladjian, Jean-Jacques
Publicado 2018

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

por Talpaz, Moshe, Kiladjian, Jean-Jacques
Publicado 2020

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

por Vaddi, Kris, Verstovsek, Srdan, Kiladjian, Jean-Jacques
Publicado 2016

Thromboembolic events in polycythemia vera

por Griesshammer, Martin, Kiladjian, Jean-Jacques, Besses, Carlos
Publicado 2019

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape

por Maslah, Nabih, Benajiba, Lina, Giraudier, Stephane, Kiladjian, Jean-Jacques, Cassinat, Bruno
Publicado 2023

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy:...

por Rey, Jérôme, Viallard, Jean-François, Keddad, Karim, Smith, Jonathan, Wilde, Paul, Kiladjian, Jean-Jacques
Publicado 2014

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

por Cassinat, Bruno, Verger, Emmanuelle, Maslah, Nabih, Gauthier, Nicolas, Vainchenker, William, Giraudier, Stéphane, Kiladjian, Jean-Jacques
Publicado 2020

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

por Ianotto, Jean-Christophe, Curto-Garcia, Natalia, Lauermanova, Marie, Radia, Deepti, Kiladjian, Jean-Jacques, Harrison, Claire N.
Publicado 2019

PB2195: CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE.

por Hoffman, Ronald, Modi, Nishit, Koschmieder, Steffen, Passamonti, Francesco, Reaven, Nancy, Gupta, Suneel, Molina, Arturo, Kiladjian, Jean-Jacques
Publicado 2023

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study

por Kiladjian, Jean-Jacques, Besses, Carlos, Griesshammer, Martin, Gugliotta, Luigi, Harrison, Claire, Coll, Ruth, Smith, Jonathan, Birgegård, Gunnar
Publicado 2012

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

por Sureau, Léa, Orvain, Corentin, Ianotto, Jean-Christophe, Ugo, Valérie, Kiladjian, Jean-Jacques, Luque Paz, Damien, Riou, Jérémie
Publicado 2021

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition

por Maslah, Nabih, Verger, Emmanuelle, Giraudier, Stéphane, Chea, Mathias, Hoffman, Ronald, Mascarenhas, John, Cassinat, Bruno, Kiladjian, Jean-Jacques
Publicado 2022

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice

por Amé, Shanti, Barraco, Fiorenza, Ianotto, Jean‐Christophe, Jourdan, Eric, Rey, Jérôme, Viallard, Jean‐François, Wémeau, Mathieu, Kiladjian, Jean‐Jacques
Publicado 2023

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safe...

por Birgegård, Gunnar, Besses, Carlos, Griesshammer, Martin, Gugliotta, Luigi, Harrison, Claire N., Hamdani, Mohamed, Wu, Jingyang, Achenbach, Heinrich, Kiladjian, Jean-Jacques
Publicado 2018

Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections

por Ghrieb, Zineb, Salmona, Maud, Michonneau, David, De Saisset, Charles, Allaoua, Souhil, Kiladjian, Jean-Jacques, Le Goff, Jérôme, Bergeron, Anne, Benajiba, Lina
Publicado 2023

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group

por Shomali, William, Colucci, Philomena, George, Tracy I., Kiladjian, Jean-Jacques, Langford, Cheryl, Patel, Jay L., Reiter, Andreas, Vannucchi, Alessandro M., Gotlib, Jason
Publicado 2023

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

por Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques
Publicado 2017

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

por Gupta, Vikas, Mascarenhas, John, Kremyanskaya, Marina, Rampal, Raajit K., Talpaz, Moshe, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Verstovsek, Srdan, Colak, Gozde, Dey, Debarshi, Harrison, Claire
Publicado 2023

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study()

por de Renzis, Benoit, Mansat-De Mas, Veronique, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Cabrespine, Aurélie, Azgui, Zahia, Ades, Lionel, Kiladjian, Jean-Jacques, Fenaux, Pierre
Publicado 2013

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis

por Buks, Ralfs, Brusson, Mégane, Cochet, Sylvie, Galochkina, Tatiana, Cassinat, Bruno, Nemazanyy, Ivan, Peyrard, Thierry, Kiladjian, Jean-Jacques, de Brevern, Alexandre G., Azouzi, Slim, El Nemer, Wassim
Publicado 2021